Ann: Launch of LUMOS2 Study, page-6

I don't know how we are going to fund ourselves through to the end of all the current trials (even though we are only providing the drug for most of them) or until any potential approval and/or commercialisation, but...

I don't know if many of you followed the conversation over at ANP on the news of James Garner jumping ship to take over the running of ANP (I hold ANP). What I found interesting over on the ANP board was the wide-held perception that Paxalisib has failed in clinical trials (the AGILE trial) and was a failed drug.

For those with patience, a risk appetite (to lose your money) and the stomach to digest further potential dilution along the way, KZA remains a worthwhile speculative punt IMHO.